<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 6, 2000
DYAX CORP.
(Exact name of registrant as specified in its charter)
DELAWARE 000-24537 04-3053198
(State of other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
ONE KENDALL SQUARE, CAMBRIDGE, MA 02139
(Address of principal executive offices and zip code)
(617) 225-2500
Registrant's telephone number, including area code:
<PAGE>
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Press release, dated November 6, 2000, of Dyax Corp.
Item 9. Regulation FD Disclosure.
On November 6, 2000, Dyax Corp., a Delaware corporation (the
"Company"), issued a press release announcing that the Company and Bracco Group
had entered into a strategic alliance to exploit diagnostic imaging and related
therapeutic applications of Dyax's proprietary phage display technology. A copy
of the press release is attached to this Current Report on Form 8-K as Exhibit
99.1.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
November 6, 2000 DYAX CORP.
/S/ STEPHEN S. GALLIKER
---------------------------------
Stephen S. Galliker
Executive Vice President, Finance
and Administration,and Chief
Financial Officer
<PAGE>
EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION
99.1 Press Release dated November 6, 2000.
